DexCom, Inc. (NASDAQ:DXCM) had its price objective dropped by equities researchers at Morgan Stanley from $72.00 to $52.00 in a note issued to investors on Friday. The brokerage presently has a “neutral” rating on the medical device company’s stock. Morgan Stanley’s target price suggests a potential upside of 5.86% from the company’s previous close.

DXCM has been the topic of several other reports. TheStreet lowered DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wedbush reissued a “buy” rating and issued a $76.00 price target on shares of DexCom in a research note on Wednesday, October 4th. Robert W. Baird reissued a “hold” rating and issued a $79.00 price target on shares of DexCom in a research note on Sunday, September 10th. Finally, Barclays PLC started coverage on DexCom in a research note on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $70.69.

Shares of DexCom (NASDAQ DXCM) traded up $1.40 during midday trading on Friday, hitting $49.12. The company had a trading volume of 1,720,582 shares, compared to its average volume of 1,705,606. The company has a current ratio of 5.86, a quick ratio of 5.84 and a debt-to-equity ratio of 0.84.

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) PT Lowered to $52.00 at Morgan Stanley” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/05/dexcom-inc-dxcm-pt-lowered-to-52-00-at-morgan-stanley.html.

In other news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $44.82, for a total value of $73,280.70. Following the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold a total of 23,208 shares of company stock valued at $1,597,567 in the last quarter. 1.70% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Independent Portfolio Consultants Inc. lifted its holdings in DexCom by 0.4% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after purchasing an additional 9 shares in the last quarter. Bbva Compass Bancshares Inc. lifted its holdings in DexCom by 1.9% during the 2nd quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after purchasing an additional 69 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its holdings in DexCom by 0.4% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after purchasing an additional 83 shares in the last quarter. World Asset Management Inc lifted its holdings in DexCom by 4.1% during the 2nd quarter. World Asset Management Inc now owns 3,901 shares of the medical device company’s stock worth $285,000 after purchasing an additional 155 shares in the last quarter. Finally, Wedbush Securities Inc. lifted its holdings in DexCom by 5.0% during the 2nd quarter. Wedbush Securities Inc. now owns 4,200 shares of the medical device company’s stock worth $307,000 after purchasing an additional 200 shares in the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.